2026年4月2日 / 美国东部时间下午4:33 / 哥伦比亚广播公司（CBS）新闻
作者：奥利维亚·里纳尔迪
奥利维亚·里纳尔迪 白宫记者
奥利维亚·里纳尔迪是哥伦比亚广播公司新闻的白宫记者，曾报道特朗普总统2024年总统竞选活动，此前曾担任《诺拉·奥唐奈主持的CBS晚间新闻》助理制片人以及《面向全国》节目广播助理。她的工作地点位于华盛顿特区。
阅读完整简历
奥利维亚·里纳尔迪
哥伦比亚广播公司新闻独家获悉，一款首创减肥药将成为特朗普总统的价格对比平台“特朗普Rx（Trump Rx）”上新增的最新药品。
Foundayo是一款GLP-1类药物，属于首创的无需空腹服用的减肥药，为厌恶打针的人群扩大了用药可及性。
一名白宫官员表示，本届政府于今年2月推出的平价药品对比网站TrumpRx将为无保险美国人提供Foundayo的优惠券，首剂售价低至149美元。
续药价格为199美元，后续处方价格为299美元。
这款减肥药也将在礼来公司的直接面向消费者平台“礼来直达（Lilly Direct）”以相近价格销售。
尽管价格相同，但一名白宫官员告诉哥伦比亚广播公司新闻，他们认为TrumpRx比药企的平台覆盖范围更广，是消费者对比市场上所有GLP-1类药物的“一站式商店”。
医保参保美国人的购药成本约为50美元，商业保险参保者约为25美元。
一名白宫官员告诉哥伦比亚广播公司新闻，这款药物最快将于周四在TrumpRx平台上架。
Foundayo同时也是美国食品药品监督管理局（FDA）优先审评券计划下获批的首款新药。该计划于去年6月公布，旨在将药品审评时间从10至12个月缩短至仅两个月。
FDA在礼来公司提交申请仅50天后就批准了这款药物。该公司计划于4月6日开始发货。
New weight loss drug to be sold on Trump’s pharmaceutical cost comparison platform
April 2, 2026 / 4:33 PM EDT / CBS News
By Olivia Rinaldi
Olivia Rinaldi White House reporter
Olivia Rinaldi is a White House reporter at CBS News. She covered President Trump’s 2024 presidential campaign and was previously an associate producer for “CBS Evening News with Norah O’Donnell” and a broadcast associate for “Face the Nation.” She is based in Washington, D.C.
Read Full Bio
Olivia Rinaldi
A first-of-its-kind weight loss pill will become the latest drug to be offered on President Trump’s cost comparison platform “Trump Rx,” CBS News exclusively learned.
Foundayo, a GLP-1 drug, is a first-of-its-kind weight loss pill that doesn’t need to be taken on an empty stomach, expanding access for those who are needle averse.
A White House official says TrumpRx, the low-cost pharmaceutical comparison website launched by the administration in February, will provide coupons for Foundayo to Americans without insurance starting at $149 for the first dose.
The refills will be marked at $199 and future prescriptions will be $299.
The pill will also be sold at a similar price on Eli Lilly’s direct to consumer platform “Lilly Direct.”
Though the prices are the same, a White House official tells CBS news they believe TrumpRx has a greater reach than the drugmaker’s platform and serves as a “one stop shop” for consumers to evaluate all GLP-1s on the market.
The cost for Americans on Medicare will be around $50 and Americans on private insurance for about $25.
A White House official told CBS News that the pill could be featured on TrumpRx as soon as Thursday.
Foundayo is also the first new drug approved under the FDA’s priority voucher program. The program, which was announced last June, was intended to shorten the time it takes to review drugs from 10 to 12 months down to just two months.
The FDA approved the Eli Lilly drug just 50 days after filing. The company plans to start shipping the pill on April 6.
发表回复